Literature DB >> 33362849

Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection.

Qiyang Ge1,2, Xuelin Huang3, Shenying Fang4, Shicheng Guo5, Yuanyuan Liu1, Wei Lin2, Momiao Xiong1.   

Abstract

Treatment response is heterogeneous. However, the classical methods treat the treatment response as homogeneous and estimate the average treatment effects. The traditional methods are difficult to apply to precision oncology. Artificial intelligence (AI) is a powerful tool for precision oncology. It can accurately estimate the individualized treatment effects and learn optimal treatment choices. Therefore, the AI approach can substantially improve progress and treatment outcomes of patients. One AI approach, conditional generative adversarial nets for inference of individualized treatment effects (GANITE) has been developed. However, GANITE can only deal with binary treatment and does not provide a tool for optimal treatment selection. To overcome these limitations, we modify conditional generative adversarial networks (MCGANs) to allow estimation of individualized effects of any types of treatments including binary, categorical and continuous treatments. We propose to use sparse techniques for selection of biomarkers that predict the best treatment for each patient. Simulations show that MCGANs outperform seven other state-of-the-art methods: linear regression (LR), Bayesian linear ridge regression (BLR), k-Nearest Neighbor (KNN), random forest classification [RF (C)], random forest regression [RF (R)], logistic regression (LogR), and support vector machine (SVM). To illustrate their applications, the proposed MCGANs were applied to 256 patients with newly diagnosed acute myeloid leukemia (AML) who were treated with high dose ara-C (HDAC), Idarubicin (IDA) and both of these two treatments (HDAC+IDA) at M. D. Anderson Cancer Center. Our results showed that MCGAN can more accurately and robustly estimate the individualized treatment effects than other state-of-the art methods. Several biomarkers such as GSK3, BILIRUBIN, SMAC are identified and a total of 30 biomarkers can explain 36.8% of treatment effect variation.
Copyright © 2020 Ge, Huang, Fang, Guo, Liu, Lin and Xiong.

Entities:  

Keywords:  causal inference; counterfactuals; generative adversarial networks; precision medicine; treatment estimation

Year:  2020        PMID: 33362849      PMCID: PMC7759680          DOI: 10.3389/fgene.2020.585804

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  23 in total

1.  Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta.

Authors:  Farah H Bardai; Santosh R D'Mello
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

2.  Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.

Authors:  Sofie Steinwascher; Anne-Lucie Nugues; Hannah Schoeneberger; Simone Fulda
Journal:  Cancer Lett       Date:  2015-05-28       Impact factor: 8.679

3.  HDAC6 regulates mitochondrial transport in hippocampal neurons.

Authors:  Sigeng Chen; Geoffrey C Owens; Helen Makarenkova; David B Edelman
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

4.  Functional proteomic profiling of AML predicts response and survival.

Authors:  Steven M Kornblau; Raoul Tibes; Yi Hua Qiu; Wenjing Chen; Hagop M Kantarjian; Michael Andreeff; Kevin R Coombes; Gordon B Mills
Journal:  Blood       Date:  2008-10-07       Impact factor: 22.113

Review 5.  Challenging Standard-of-Care Paradigms in the Precision Oncology Era.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  Trends Cancer       Date:  2018-01-12

6.  Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Guillermo Garcia-Manero; Francesco Paolo Tambaro; Nebiyou B Bekele; Hui Yang; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Tapan M Kadia; Marina Y Konopleva; Stefan Faderl; Jorge E Cortes; Mark Brandt; Yumin Hu; Deborah McCue; Willie Mae Newsome; Sherry R Pierce; Marcos de Lima; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

7.  Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Authors:  Daniel A Pollyea; Martin S Tallman; Stéphane de Botton; Hagop M Kantarjian; Robert Collins; Anthony S Stein; Mark G Frattini; Qiang Xu; Alessandra Tosolini; Wendy L See; Kyle J MacBeth; Samuel V Agresta; Eyal C Attar; Courtney D DiNardo; Eytan M Stein
Journal:  Leukemia       Date:  2019-04-09       Impact factor: 12.883

Review 8.  Addressing the challenges of applying precision oncology.

Authors:  Seung Ho Shin; Ann M Bode; Zigang Dong
Journal:  NPJ Precis Oncol       Date:  2017-09-04

9.  STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.

Authors:  Damian Szklarczyk; Annika L Gable; David Lyon; Alexander Junge; Stefan Wyder; Jaime Huerta-Cepas; Milan Simonovic; Nadezhda T Doncheva; John H Morris; Peer Bork; Lars J Jensen; Christian von Mering
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

10.  The reactome pathway knowledgebase.

Authors:  Bijay Jassal; Lisa Matthews; Guilherme Viteri; Chuqiao Gong; Pascual Lorente; Antonio Fabregat; Konstantinos Sidiropoulos; Justin Cook; Marc Gillespie; Robin Haw; Fred Loney; Bruce May; Marija Milacic; Karen Rothfels; Cristoffer Sevilla; Veronica Shamovsky; Solomon Shorser; Thawfeek Varusai; Joel Weiser; Guanming Wu; Lincoln Stein; Henning Hermjakob; Peter D'Eustachio
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

View more
  1 in total

1.  Protocol for the development of a reporting guideline for causal and counterfactual prediction models in biomedicine.

Authors:  Jie Xu; Yi Guo; Fei Wang; Hua Xu; Robert Lucero; Jiang Bian; Mattia Prosperi
Journal:  BMJ Open       Date:  2022-06-20       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.